Overview of the Annual General Meeting Voting Results
Knight Therapeutics Inc. (TSX:GUD), a leading specialty pharmaceutical company based in Montreal, has recently announced the outcomes of its Annual General Meeting. The event, which was conducted virtually, focused on crucial matters including the election of directors, the appointment of external auditors, and the renewal of employee share purchase plan rights.
Election of Directors
Directors Elected
All director nominees presented during the shareholder meeting received overwhelming support and were elected to the board. Here’s a brief insight into the voting results for each nominee:
Nominee Results:
Jonathan Ross Goodman achieved 96.70% in favor, reflecting strong approval, while James C. Gale received an impressive 99.14% of votes. Other elected directors included Samira Sakhia with a 99.86% approval rate, Robert N. Lande at 99.66%, and Michael J. Tremblay earning 96.13% support. Nicolás Sujoy and Janice Murray also gained strong votes of 99.67% each.
Appointment of External Auditors
Continuing Partnership with Ernst & Young LLP
The shareholders voted overwhelmingly to appoint Ernst & Young LLP as external auditors for Knight Therapeutics for the upcoming year. With 99.60% of the votes cast in favor of this appointment, the collaboration with Ernst & Young is set to continue, supporting the company's financial transparency and accountability.
Employee and Director Share Purchase Plan
Renewal of Unallocated Rights
The resolution to renew the unallocated rights under the employee and director share purchase plan was successfully approved. This reflects the company’s commitment to align the interests of its employees and directors with those of the shareholders. The approval received 87.82% of the votes for the renewal.
Conclusion
The successful outcome of this meeting not only demonstrates confidence in the leadership of Knight Therapeutics Inc., represented by the strong approval for director elections and the auditors' appointment, but it also showcases the commitment of shareholders to support the company's growth and governance strategies. As Knight Therapeutics continues to acquire and commercialize pharmaceutical products for Canada and Latin America, the focus remains on delivering value to all stakeholders.
For more detailed information regarding the Annual General Meeting and its outcomes, shareholders and interested parties are encouraged to visit the official documents available in the public domain.
Contact Information for Investor Inquiries
For any investor-related inquiries, you can reach out to:
Samira Sakhia, President & Chief Executive Officer at Knight Therapeutics Inc.
Phone: 514.484.4483
Email: IR@knighttx.com
Frequently Asked Questions
What is Knight Therapeutics Inc.?
Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products primarily in Canada and Latin America.
Who were elected as directors during the meeting?
Directors elected included Jonathan Ross Goodman, James C. Gale, Samira Sakhia, Robert N. Lande, Michael J. Tremblay, Nicolás Sujoy, and Janice Murray.
What percentage of votes did external auditors receive?
Ernst & Young LLP received 99.60% of votes in favor of their appointment as external auditors.
What does the share purchase plan entail?
The share purchase plan allows employees and directors to acquire shares in the company, aligning their interests with that of the shareholders.
How can I find more information about Knight Therapeutics?
More information can be accessed on the official website of Knight Therapeutics or through their annual reports available in public records.
